Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Tesla, Inc. — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 25.2× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and Tesla, Inc. for 88 Days on average.
| TAK | TSLA | |
|---|---|---|
Market Cap | $58.74B | $1.48T |
Volume | 3,110,994 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $19.05 | $489.88 |
52-Week Low | $13.23 | $298.16 |
Typical Hold Time | 1 Days | 88 Days |
Enterprise Value | $86.65B | $1.45T |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tesla (TSLA) trades at $375.03, down 0.68% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed earnings, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue at $94.83B in 2025 and a net income margin of 4%. Analyst consensus is a Buy with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and high valuation multiples. The stock offers growth potential from AI and robotics expansion, but faces headwinds from competitive pressures and margin compression. Investors should weigh long-term disruptive potential against current profitability challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
